FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BERTHELSEN SPENCER R
2. Issuer Name and Ticker or Trading Symbol

ISIS PHARMACEUTICALS INC [ ISIS ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O ISIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT
3. Date of Earliest Transaction (MM/DD/YYYY)

7/1/2015
(Street)

CARLSBAD, CA 92010
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   7/1/2015   7/1/2015   M (1)    469   A $0   60864   D  
 
Common Stock   7/1/2015   7/1/2015   M (2)    667   A $0   61531   D  
 
Common Stock   7/2/2015   7/2/2015   M (3)    312   A $0   61843   D  
 
Common Stock                  70   (4) I   By Daughter  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units     (5) 7/1/2015   7/1/2015   M         469      (6)   (6) Common Stock   469   $0   937   D  
 
Restricted Stock Units     (5) 7/1/2015   7/1/2015   M         667      (7)   (7) Common Stock   667   $0   2000   D  
 
Restricted Stock Units     (5) 7/2/2015   7/2/2015   M         312      (8)   (8) Common Stock   312   $0   312   D  
 
Restricted Stock Units     (5) 7/1/2015   7/1/2015   A      2667         (9)   (9) Common Stock   2667   $0   2667   D  
 
Director Stock Option (right to buy)   $57.16   7/1/2015   7/1/2015   A      16000       7/1/2016   (10) 6/30/2025   (10) Common Stock   16000   $0   16000   D  
 

Explanation of Responses:
( 1)  Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on July 1, 2013.
( 2)  Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on July 1, 2014.
( 3)  Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on July 2, 2012.
( 4)  The reporting person disclaims beneficial ownership of all securities held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
( 5)  Each Restricted Stock Unit represents a contingent right to receive one share of Isis common stock, or its equivalent cash value.
( 6)  Restricted Stock Unit Award granted on July 1, 2013. Restricted Stock Units vest in equal annual installments, the first installment vested on July 1, 2014. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2017.
( 7)  Restricted Stock Unit Award granted on July 1, 2014. Restricted Stock Units vest in equal annual installments, the first installment vested on July 1, 2015. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2018.
( 8)  Restricted Stock Unit Award granted on July 2, 2012. Restricted Stock Units vest in equal annual installments, the first installment vested on July 2, 2013. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 2, 2016.
( 9)  Grant of July 1, 2015 to reporting person of Restricted Stock Unit Award under the Isis Pharmacueticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 1, 2016. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2019. The RSU is vested as to 0 shares on July 1, 2015.
( 10)  Grant of July 1, 2015 to reporting person of stock options under the Isis Pharmacueticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on 7/1/2016. The option shall be fully vested and exercisable on 7/1/2019. The stock option was exercisable as to 0 shares on 7/1/2015.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BERTHELSEN SPENCER R
C/O ISIS PHARMACEUTICALS, INC.
2855 GAZELLE COURT
CARLSBAD, CA 92010
X



Signatures
/s/B. Lynne Parshall, attorney-in-fact 7/2/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Ionis Pharmaceuticals Charts.
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Ionis Pharmaceuticals Charts.